White Paul F, Tufanogullari Burcu, Taylor Jimmie, Klein Kevin
Department of Anesthesiology and Pain Management, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Boulevard, Dallas, TX 75390-9068, USA.
Anesth Analg. 2009 Apr;108(4):1140-5. doi: 10.1213/ane.0b013e31818d40ce.
Pregabalin is a gabapentinoid compound, which has been alleged to possess anxiolytic, analgesic, and anticonvulsant properties. We hypothesized that premedication with oral pregabalin would produce dose-related reductions in acute (state) anxiety and increases in sedation (sleepiness) before induction of general anesthesia. A secondary objective was to determine if premedication with pregabalin would reduce postoperative pain.
One hundred eight ASA I-III outpatients undergoing elective surgery were randomly assigned to one of the four premedication treatment groups: 1) control group received placebo capsules, 2) pregabalin 75 group received pregabalin 75 mg, po, 3) pregabalin 150 group received pregabalin 150 mg, po, and 4) pregabalin 300 group received pregabalin 300 mg, po. The effects of the study drug on the patients' level of anxiety, sedation, and pain were assessed at baseline (immediately before study drug administration), at 30 and 60 min after drug administration, and immediately before induction of anesthesia, as well as at 30-min intervals in the postanesthesia care unit (PACU) using standardized 11-point verbal rating scales, with 0 = none to 10 = maximal effect. The need for postoperative opioid analgesic medication, incidence of nausea and vomiting, requirement for rescue antiemetics, and times to discharge from the PACU and hospital, as well as the patients' quality of recovery scores, and late recovery outcomes (e.g., resumption of dietary intake and recovery of bowel function) were assessed at a 7-day follow-up interview.
Demographic characteristics, times between study drug administration to anesthetic induction, type of surgical procedures, duration of anesthesia, PACU and hospital discharge time, as well as the requirement for fentanyl in the PACU, did not differ among the four study groups. Anxiety levels remained unchanged during the preoperative evaluation period, and did not differ among the four study groups. Sedation scores were significantly higher in the pregabalin 300 group at the preinduction assessment interval and at 90 and 120 min after surgery compared with the control group (5 +/- 3 vs 3 +/- 2, 7 +/- 4 vs 5 +/- 3, 8 +/- 4 vs 4 +/- 4, respectively, P < 0.05).
Preoperative pregabalin administration (75-300 mg po) increased perioperative sedation in a dose-related fashion, but failed to reduce preoperative state anxiety, postoperative pain, or to improve the recovery process after minor elective surgery procedures.
普瑞巴林是一种加巴喷丁类化合物,据称具有抗焦虑、镇痛和抗惊厥特性。我们假设术前口服普瑞巴林会在全身麻醉诱导前产生与剂量相关的急性(状态)焦虑减轻和镇静(嗜睡)增加。第二个目标是确定术前使用普瑞巴林是否会减轻术后疼痛。
108例接受择期手术的美国麻醉医师协会(ASA)I - III级门诊患者被随机分配到四个术前用药治疗组之一:1)对照组接受安慰剂胶囊;2)普瑞巴林75组口服75毫克普瑞巴林;3)普瑞巴林150组口服150毫克普瑞巴林;4)普瑞巴林300组口服300毫克普瑞巴林。使用标准化的11分语言评定量表,在基线(给药前即刻)、给药后30和60分钟、麻醉诱导前以及麻醉后护理单元(PACU)每隔30分钟评估研究药物对患者焦虑、镇静和疼痛水平的影响,量表范围为0 =无影响至10 =最大影响。在7天的随访访谈中评估术后阿片类镇痛药的需求、恶心和呕吐的发生率、急救止吐药的需求、从PACU和医院出院的时间,以及患者的恢复质量评分和后期恢复结果(如饮食摄入恢复和肠功能恢复)。
四个研究组在人口统计学特征、给药至麻醉诱导的时间、手术类型、麻醉持续时间、PACU和医院出院时间以及PACU中芬太尼的需求方面没有差异。术前评估期间焦虑水平保持不变,四个研究组之间没有差异。与对照组相比,普瑞巴林300组在诱导前评估间隔以及术后90和120分钟时的镇静评分显著更高(分别为5±3对3±2、7±4对5±3、8±4对4±4,P < 0.05)。
术前给予普瑞巴林(口服75 - 300毫克)以剂量相关的方式增加围手术期镇静,但未能减轻术前状态焦虑、术后疼痛,也未改善小型择期手术术后的恢复过程。